The vaccine for monkeypox, developed by researchers at the National Research Center for Epidemiology and Microbiology named after NF Gamaleya, is designed to offer protection against all forms of monkeypox as well as smallpox. This information was shared by Alexander Ginzburg, who leads the center, via TASS. The developers emphasize that the vaccine targets all monkeypox variants and is also expected to provide preventive defense against smallpox because of the close immunological relationship between the two diseases, around 97-98% similarity in protection profiles.
The project underscores a comprehensive approach: a vaccine that covers multiple monkeypox strains while extending cross-protection to smallpox. The researchers note that the immunological link between monkeypox and smallpox enables broader defensive coverage, which could be crucial in curbing outbreaks that may cross species or regional boundaries. This claim, while promising, is anchored in laboratory and early clinical observations that compare antigenic similarities and immune responses elicited by the vaccine against both viruses.
In related developments, the World Health Organization has stated that wearing masks is not compulsory in the context of the ongoing outbreak, given current epidemiological assessments. This stance reflects a shift toward voluntary protective measures and risk-based guidance for the general public, with emphasis on targeted precautions in high-risk settings rather than universal mandates.
On the African continent, President Cyril Ramaphosa announced on August 17 that more than 17 thousand monkeypox cases had been reported across Africa in 2024. The figure highlights the continued vigilance required from public health authorities, especially in regions where healthcare resources may be stretched and where vaccination campaigns and surveillance systems are being expanded to detect and respond to emerging cases. The situation serves as a reminder of the potential for outbreaks to persist or re-emerge, reinforcing the need for vaccines, rapid diagnostics, and effective public health messaging.
Earlier conversations in Russia addressed whether an effective monkeypox vaccine had been identified. Experts emphasized that the ongoing research and development efforts in this area aim to establish a vaccine capable of broad protection, alongside strategies for monitoring, surveillance, and containment of potential outbreaks. The dialogue reflects a global interest in robust immunization options that can adapt to evolving epidemiological patterns and provide durable protection for diverse populations.